Radiotherapy with continued EGFR‐TKIs for oligoprogressive disease in EGFR‐mutated non‐small cell lung cancer: A real‐world study-Reference-Cited by-同舟云学术

Radiotherapy with continued EGFR‐TKIs for oligoprogressive disease in EGFR‐mutated non‐small cell lung cancer: A real‐world study

Published:2022-06-05 Issue:1 Volume:12 Page:266-273
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Hu Chunhong¹,Wu Sixuan¹²,Deng Renfang¹³,Wu Yuanqiang¹,Pan Yue¹,Shu Long¹,Wu Fang¹⁴⁵⁶^ORCID

Affiliation:

1. Department of Oncology The Second Xiangya Hospital, Central South University Changsha Hunan China

2. Department of Internal Medicine Oncology The First Affiliated Hospital of University of South China Hengyang Hunan Province China

3. Department of Oncology ZhuZhou Second Hospital ZhuZhou Hunan China

4. Hunan Cancer Mega‐Data Intelligent Application and Engineering Research Centre Changsha Hunan China

5. Hunan Key Laboratory of Tumor Models and Individualized Medicine The Second Xiangya Hospital, Central South University Changsha Hunan China

6. Hunan Key Laboratory of Early Diagnosis and Precision Therapy in Lung Cancer The Second Xiangya Hospital, Central South University Changsha Hunan China

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4894

Reference18 articles.

1. Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment

2. Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives

3. The biology and management of non-small cell lung cancer

4. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

5. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Appropriate delay of primary tumour radiotherapy may lead to better long-term overall survival for non-small cell lung cancer treated with EGFR-TKIs;BMC Cancer;2024-08-26

2. Outcomes Analysis of Patients Receiving Local Ablative Therapy for Oligoprogressive Metastatic NSCLC Under First-Line Immunotherapy;Clinical Lung Cancer;2024-08

3. Local control strategies for management of NSCLC with oligoprogressive disease;Cancer Treatment Reviews;2023-11

4. The Emerging Role of Radiotherapy in Oligoprogressive Non-Small Cell Lung Cancer;Surgical Oncology Clinics of North America;2023-07

5. Impact of thoracic tumor radiotherapy on survival in non‐small‐cell lung cancer with malignant pleural effusion treated with targeted therapy: Propensity score matching study;Cancer Medicine;2023-06-08